Packaging Size | 40 capsule |
Strength | 200mg |
Composition | Molnupiravir |
Treatment | Covid |
Prescription/Non prescription | Prescription |
Form | Tablet |
Brand | Movifor |
Manufacturer | Hetero |
Shelf life | 18 months |
Also gives | Third Party Manufacturing, PCD Pharma |
Packaging Type | Bottles |
Movfor Capsule is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.
Movfor Capsule is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.